Mechanisms of inflammatory response syndrome in sepsis

Drug Discovery Today: Disease Mechanisms

Volumn 1, Issue 3, 2004, Pages 345-350

  Hoesel, Laszlo M ^a   Ward, Peter A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE INHIBITOR; COMPLEMENT; GLUCOCORTICOID; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; LECTIN; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; ENDOTHELIUM CELL; EPITHELIUM CELL; GRAM POSITIVE BACTERIUM; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNOSTIMULATION; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; NEUTROPHIL; NONHUMAN; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PHAGOCYTE; REVIEW; SEPSIS; SEPTIC SHOCK;

EID: 23744507023     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2004.11.003     Document Type: Review

References (30)

1. Ward, P.A. (2004) The dark side of C5a in sepsis. Nat. Rev. Immunol. 4, 133-142
2. Angus, D.C. et al. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303-1310
3. Bone, R.C. et al. (1989) Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit. Care Med. 17, 389-393
4. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 20, 864-874
5. Levy, M.M. et al. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 29, 530-538
6. Abraham, E. et al. (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. J. Am. Med. Assoc. 273, 934-941
7. Adams, D.H. and Shaw, S. (1994) Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 343, 831-836
8. Riedemann, N.C. et al. (2004) Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis. FASEB J. 18, 370-372
9. Bone, R.C. (1996) Sir Isaac Newton, sepsis, SIRS, and CARS. Crit. Care Med. 24, 1125-1128
10. Hotchkiss, R.S. and Karl, I.E. (2003) The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 138-150
11. Riedemann, N.C. et al. (2003) Novel strategies for the treatment of sepsis. Nat. Med. 9, 517-524
12. Wang, J.E. et al. (2000) Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model. Infect. Immun. 68, 3965-3970
13. Ohlsson, K. et al. (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348, 550-552
14. Riedemann, N.C. et al. (2003) Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J. Immunol. 170, 503-507
15. Wright, S.D. et al. (1990) CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249, 1431-1433
16. Landmann, R. et al. (1995) Increased circulating soluble CD14 is associated with high mortality in Gram-negative septic shock. J. Infect. Dis. 171, 639-644
17. Leturcq, D.J. et al. (1996) Antibodies against CD14 protect primates from endotoxin-induced shock. J. Clin. Invest. 98, 1533-1538
18. Aderem, A. and Ulevitch, R.J. (2000) Toll-like receptors in the induction of the innate immune response. Nature 406, 782-787
19. Petersen, S.V. et al. (2001) The mannan-binding lectin pathway of complement activation: biology and disease association. Mol. Immunol. 38, 133-149
20. Cain, S.A. and Monk, P.N. (2002) The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). J. Biol. Chem. 277, 7165-7169
21. Calandra, T. et al. (2000) Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. 6, 164-170
22. Gorgen, I. et al. (1992) Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-alpha. J. Immunol. 149, 918-924
23. O'Reilly, M. et al. (1992) Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. J. Trauma 33, 679-682
24. Oberholzer, C. et al. (2001) Apoptosis in sepsis: a new target for therapeutic exploration. FASEB J. 15, 879-892
25. Hotchkiss, R.S. et al. (1999) Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc. Natl. Acad. Sci. USA 96, 14541-14546
26. Hotchkiss, R.S. et al. (1999) Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J. Immunol. 162, 4148-4156
27. Healy, D.P. (2002) New and emerging therapies for sepsis. Ann. Pharmacother. 36, 648-654
28. van der Poll, T. (2001) Immunotherapy of sepsis. Lancet Infect. Dis. 1, 165-174
29. Vincent, J.L. et al. (2002) Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin. Infect. Dis. 34, 1084-1093
30. van den Berghe, G. et al. (2001) Intensive insulin therapy in the critically ill patients. N. Engl. J. Med. 345, 1359-1367